Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 541 | 48 | 388 |
| Samples | 120 | 23 | 95 |
| Peptides | 121 | 14 | 81 |
Function
CXCR6 · C-X-C motif chemokine receptor 6
The protein encoded by this gene is a G protein-coupled receptor with seven transmembrane domains that belongs to the CXC chemokine receptor family. This family also includes CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, and CXCR7. This gene, which maps to the chemokine receptor gene cluster, is expressed in several T lymphocyte subsets and bone marrow stromal cells. The encoded protein and its exclusive ligand, chemokine ligand 16 (CCL16), are part of a signalling pathway that regulates T lymphocyte migration to various peripheral tissues (the liver, spleen red pulp, intestine, lungs, and skin) and promotes cell-cell interaction with dendritic cells and fibroblastic reticular cells. CXCR6/CCL16 also controls the localization of resident memory T lymphocytes to different compartments of the lung and maintains airway resident memory T lymphocytes, which are an important first line of defense against respiratory pathogens. The encoded protein serves as an entry coreceptor used by HIV-1 and SIV to enter target cells, in conjunction with CD4. [provided by RefSeq, Aug 2020].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 121 amino-acid changes on canonical ENST00000304552 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CXCR6 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CXCR6 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 5/42 12% | 11/612 2% |
| Melanoma | 4/210 2% | 18/1899 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Bladder Carcinoma | 1/58 2% | 4/956 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Colorectal Carcinoma | 2/143 1% | 13/3239 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Ovarian Carcinoma | 1/109 1% | 3/998 0% |
| Gastric Carcinoma | 0/74 0% | 6/1809 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Biliary Tract Carcinoma | 1/54 2% | 2/950 0% |
| Glioma | 0/52 0% | 6/2127 0% |
| Kidney Carcinoma | 1/85 1% | 4/1862 0% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 4/1390 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 0/810 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Other Solid Cancers | 1/94 1% | 2/1515 0% |
| Head and Neck Carcinoma | 2/85 2% | 1/1574 0% |
| Pancreatic Carcinoma | 0/89 0% | 3/1611 0% |
| Breast Carcinoma | 2/144 1% | 3/3264 0% |
| Neuroendocrine Tumour | 0/154 0% | 1/577 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Hepatocellular Carcinoma | 0/46 0% | 3/2210 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 1/1592 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
| Other Blood Cancers | 0/61 0% | 1/2725 0% |
| B-Lymphoblastic Leukemia | 0/55 0% | 1/2640 0% |
Mutation Distribution
Where CXCR6 is mutated · all tissues, split by cell line vs tissue
How many mutations in CXCR6 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 541 mutations in CXCR6
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|